Proactiveinvestors recommends
Additional Information
Market: ASX
Sector: Pharmaceuticals
EPIC: SPL
Latest Price: 1.37  (1.11% Ascending)
52-week High: 1.66
52-week Low: 0.96
Market Cap: 338.56M
1 year chart
digital-look imported chart image
1 day chart
digital-look imported chart image
Starpharma
www.starpharma.com

Starpharma is a world leader in the development of dendrimer nanotechnology for pharmaceutical, life-science and other applications.  The lead pharmaceutical development product is VivaGel®, a vaginal microbicide designed to prevent the transmission of HIV and genital herpes.  Starpharma is developing a VivaGel®-coated condom under a licence agreement with SSL International plc (LSE:SSL), manufacturer of Durex®, the market-leading condom brand worldwide.  Products based on Starpharma’s technology are on the market as diagnostic elements and laboratory reagents through licence arrangements with partners including Siemens and Merck KgA.  Starpharma is exploring dendrimer opportunities in materials science applications including water remediation and animal health products.

Full Starpharma profile here
Pdf

Starpharma Holdings reports positve results from VivaGel® clinical trial

12th Mar 2010, 2:04 pm
Starpharma Holdings reports positve results from VivaGel® clinical trial

Australian pharmaceutical development company Starpharma Holdings (ASX:SPL, OTCQX:SPHRY) has received positive results from a clinical trial of the company's 3% SPL7013 Gel (VivaGel®) product.

It was found to be comparable in terms of safety and tolerability with its matched placebo when administered vaginally, twice daily for 14 days in sexually active women involved in the trial.

Starpharma CEO, Dr Jackie Fairley, said, the data from the study provided further evidence of the safety and tolerability of the VivaGel® active ingredient, SPL7013, and will support its development as both a stand-alone gel (bacterial vaginosis, genital herpes and HIV), and as a condom coating.

The study enrolled 61 healthy women who vaginally applied VivaGel®, a matched placebo gel without the SPL7013 active ingredient, or an alternative experimental placebo based on hydroxyethyl cellulose (HEC).

Starpharma plans to commence further clinical studies of VivaGel®, including a phase 2 efficacy study in bacterial vaginosis, during 2010.

The clinical study was funded by the Division of AIDS (DAIDS), National Institute of Allergy and Infectious Diseases (NIAID), and the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institutes of Health (NIH).

No investment advice

The Company is a publisher and is not registered with or authorised by the Financial Services Authority (FSA). You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.